{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T20:43:54Z","timestamp":1789073034783,"version":"build-2803163510"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,2,22]],"date-time":"2022-02-22T00:00:00Z","timestamp":1645488000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,22]],"date-time":"2022-02-22T00:00:00Z","timestamp":1645488000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Biol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>SARS-CoV-2 has an exonuclease-based proofreader, which removes nucleotide inhibitors such as Remdesivir that are incorporated into the viral RNA during replication, reducing the efficacy of these drugs for treating COVID-19. Combinations of inhibitors of both the viral RNA-dependent RNA polymerase and the exonuclease could overcome this deficiency. Here we report the identification of hepatitis C virus NS5A inhibitors Pibrentasvir and Ombitasvir as SARS-CoV-2 exonuclease inhibitors. In the presence of Pibrentasvir, RNAs terminated with the active forms of the prodrugs Sofosbuvir, Remdesivir, Favipiravir, Molnupiravir and AT-527 were largely protected from excision by the exonuclease, while in the absence of Pibrentasvir, there was rapid excision. Due to its unique structure, Tenofovir-terminated RNA was highly resistant to exonuclease excision even in the absence of Pibrentasvir. Viral cell culture studies also demonstrate significant synergy using this combination strategy. This study supports the use of combination drugs that inhibit both the SARS-CoV-2 polymerase and exonuclease for effective COVID-19 treatment.<\/jats:p>","DOI":"10.1038\/s42003-022-03101-9","type":"journal-article","created":{"date-parts":[[2022,2,22]],"date-time":"2022-02-22T06:02:51Z","timestamp":1645509771000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":60,"title":["Combination of antiviral drugs inhibits SARS-CoV-2 polymerase and exonuclease and demonstrates COVID-19 therapeutic potential in viral cell culture"],"prefix":"10.1038","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4198-7388","authenticated-orcid":false,"given":"Xuanting","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina Q.","family":"Sacramento","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4592-5280","authenticated-orcid":false,"given":"Steffen","family":"Jockusch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6211-7659","authenticated-orcid":false,"given":"Ot\u00e1vio Augusto","family":"Chaves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanjuan","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Fintelman-Rodrigues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minchen","family":"Chien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8092-2149","authenticated-orcid":false,"given":"Jairo R.","family":"Temerozo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiv","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9779-7778","authenticated-orcid":false,"given":"Dinshaw J.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cindy","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6270-1369","authenticated-orcid":false,"given":"Aitor","family":"Garzia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Tuschl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8349-9529","authenticated-orcid":false,"given":"Patr\u00edcia T.","family":"Bozza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James J.","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2212-3899","authenticated-orcid":false,"given":"Thiago Moreno L.","family":"Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4974-4241","authenticated-orcid":false,"given":"Jingyue","family":"Ju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,22]]},"reference":[{"key":"3101_CR1","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1056\/NEJMoa2001017","volume":"382","author":"N Zhu","year":"2020","unstructured":"Zhu, N. et al. A novel coronavirus from patients with pneumonia in China, 2019. N. Eng. J. Med. 382, 727\u2013733 (2020).","journal-title":"N. Eng. J. Med."},{"key":"3101_CR2","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/s41579-020-00468-6","volume":"19","author":"P V\u2019kovski","year":"2021","unstructured":"V\u2019kovski, P. et al. Coronavirus biology and replication: implications for SARS-CoV-2. Nat. Rev. Microbiol. 19, 155\u2013170 (2021).","journal-title":"Nat. Rev. Microbiol."},{"key":"3101_CR3","doi-asserted-by":"publisher","first-page":"104793","DOI":"10.1016\/j.antiviral.2020.104793","volume":"178","author":"A Shannon","year":"2020","unstructured":"Shannon, A. et al. Remdesivir and SARS-CoV-2: structural requirements at both nsp12 RdRp and nsp14 exonuclease active-sites. Antivir. Res. 178, 104793 (2020).","journal-title":"Antivir. Res."},{"key":"3101_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-10280-3","volume":"10","author":"RN Kirchdoerfer","year":"2019","unstructured":"Kirchdoerfer, R. N. & Ward, A. B. Structure of the SARS-CoV nsp12 polymerase bound to nsp7 and nsp8 co-factors. Nat. Commun. 10, 2342 (2019).","journal-title":"Nat. Commun."},{"key":"3101_CR5","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1126\/science.abb7498","volume":"368","author":"Y Gao","year":"2020","unstructured":"Gao, Y. et al. Structure of the RNA-dependent RNA polymerase from COVID-19 virus. Science 368, 779\u2013782 (2020).","journal-title":"Science"},{"key":"3101_CR6","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/s41586-020-2368-8","volume":"584","author":"HS Hillen","year":"2020","unstructured":"Hillen, H. S. et al. Structure of replicating SARS-CoV-2 polymerase. Nature 584, 154\u2013156 (2020).","journal-title":"Nature"},{"key":"3101_CR7","doi-asserted-by":"publisher","first-page":"9372","DOI":"10.1073\/pnas.1201130109","volume":"109","author":"M Bouvet","year":"2012","unstructured":"Bouvet, M. et al. RNA 3\u2032-end mismatch excision by the severe acute respiratory syndrome coronavirus nonstructural protein nsp10\/nsp14 exoribonuclease complex. Proc. Natl Acad. Sci. USA 109, 9372\u20139377 (2012).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"3101_CR8","doi-asserted-by":"publisher","unstructured":"Ju, J. et al. Nucleotide analogues as inhibitors of viral polymerases. Preprint at bioRXiv https:\/\/doi.org\/10.1101\/2020.01.30.927574 (2020).","DOI":"10.1101\/2020.01.30.927574"},{"key":"3101_CR9","doi-asserted-by":"publisher","first-page":"e00674","DOI":"10.1002\/prp2.674","volume":"8","author":"J Ju","year":"2020","unstructured":"Ju, J. et al. Nucleotide analogues as inhibitors of SARS-CoV polymerase. Pharmacol. Res. Perspect. 8, e00674 (2020).","journal-title":"Pharmacol. Res. Perspect."},{"key":"3101_CR10","doi-asserted-by":"publisher","first-page":"104857","DOI":"10.1016\/j.antiviral.2020.104857","volume":"180","author":"S Jockusch","year":"2020","unstructured":"Jockusch, S. et al. A library of nucleotide analogues terminate RNA synthesis catalyzed by polymerases of coronaviruses that cause SARS and COVID-19. Antivir. Res. 180, 104857 (2020).","journal-title":"Antivir. Res."},{"key":"3101_CR11","doi-asserted-by":"publisher","first-page":"4690","DOI":"10.1021\/acs.jproteome.0c00392","volume":"19","author":"M Chien","year":"2020","unstructured":"Chien, M. et al. Nucleotide analogues as inhibitors of SARS-CoV-2 polymerase, a key drug target for COVID-19. J. Proteome Res. 19, 4690\u20134697 (2020).","journal-title":"J. Proteome Res."},{"key":"3101_CR12","doi-asserted-by":"publisher","first-page":"3379","DOI":"10.1093\/jac\/dkaa334","volume":"75","author":"A Sadeghi","year":"2020","unstructured":"Sadeghi, A. et al. Sofosbuvir and daclatasvir compared with standard of care in the treatment of patients admitted to hospital with moderate or severe coronavirus infection (COVID-19): a randomized controlled trial. J. Antimicrob. Chemother. 75, 3379\u20133385 (2020).","journal-title":"J. Antimicrob. Chemother."},{"key":"3101_CR13","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1080\/13543776.2021.1880568","volume":"31","author":"I Vicenti","year":"2021","unstructured":"Vicenti, I., Zazzi, M. & Saladini, F. SARS-CoV-2 RNA-dependent RNA polymerase as a therapeutic target for COVID-19. Expert Opin. Ther. Pat. 31, 325\u2013337 (2021).","journal-title":"Expert Opin. Ther. Pat."},{"key":"3101_CR14","doi-asserted-by":"publisher","first-page":"6785","DOI":"10.1074\/jbc.RA120.013679","volume":"295","author":"CJ Gordon","year":"2020","unstructured":"Gordon, C. J. et al. Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency. J. Biol. Chem. 295, 6785\u20136797 (2020).","journal-title":"J. Biol. Chem."},{"key":"3101_CR15","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1016\/j.molcel.2021.01.035","volume":"81","author":"JPK Bravo","year":"2021","unstructured":"Bravo, J. P. K., Dangerfield, T. L., Taylor, D. W. & Johnson, K. A. Remdesivir is a delayed translocation inhibitor of SARS-CoV-2 replication. Molec. Cell 81, 1548\u20131552 (2021).","journal-title":"Molec. Cell"},{"key":"3101_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-73641-9","volume":"10","author":"S Jockusch","year":"2020","unstructured":"Jockusch, S. et al. Sofosbuvir terminated RNA is more resistant to SARS-CoV-2 proofreader than RNA terminated by remdesivir. Sci. Rep. 10, 16577 (2020).","journal-title":"Sci. Rep."},{"key":"3101_CR17","doi-asserted-by":"publisher","first-page":"647693","DOI":"10.3389\/fmicb.2021.647693","volume":"12","author":"S Khater","year":"2021","unstructured":"Khater, S. et al. Combining SARS-CoV-2 proofreading exonuclease and RNA-dependent RNA polymerase inhibitors as a strategy to combat COVID-19: a high-throughput in silico screen. Front. Microbiol. 12, 647693 (2021).","journal-title":"Front. Microbiol."},{"key":"3101_CR18","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1177\/1060028015610342","volume":"50","author":"MA Smith","year":"2016","unstructured":"Smith, M. A., Regal, R. E. & Mohammad, R. A. Daclatasvir: a NS5A replication complex inhibitor for hepatitis C infection. Ann. Pharmacother. 50, 39\u201346 (2016).","journal-title":"Ann. Pharmacother."},{"key":"3101_CR19","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1038\/s41586-020-2286-9","volume":"583","author":"DE Gordon","year":"2020","unstructured":"Gordon, D. E. et al. A SARS-CoV-2 protein- interaction map reveals targets for drug repurposing. Nature 583, 459\u2013468 (2020).","journal-title":"Nature"},{"key":"3101_CR20","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1093\/jac\/dkab072","volume":"76","author":"C Sacramento","year":"2021","unstructured":"Sacramento, C. et al. In vitro antiviral activity of the anti-HCV drugs daclatasvir and sofosbuvir against SARS-CoV-2, the aetiological agent of COVID-19. J. Antimicrob. Chemother. 76, 1874\u20131885 (2021).","journal-title":"J. Antimicrob. Chemother"},{"key":"3101_CR21","unstructured":"Sanders, R. Can hepatitis C drugs help remdesivir fight COVID-19? https:\/\/news.berkeley.edu\/2021\/02\/03\/can-hepatitis-c-drugs-help-remdesiver-fight-covid-19\/ (2021)."},{"key":"3101_CR22","doi-asserted-by":"publisher","unstructured":"Nguyenla, X. et al. Discovery of SARS-CoV-2 antiviral synergy between remdesivir and approved drugs in human lung cells. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2020.09.18.302398 (2020).","DOI":"10.1101\/2020.09.18.302398"},{"key":"3101_CR23","doi-asserted-by":"publisher","first-page":"4682","DOI":"10.1038\/s41467-020-18463-z","volume":"11","author":"A Shannon","year":"2020","unstructured":"Shannon, A. et al. Rapid incorporation of favipiravir by the fast and permissive viral RNA polymerase complex results in SARS-CoV-2 lethal mutagenesis. Nat. Commun. 11, 4682 (2020).","journal-title":"Nat. Commun."},{"key":"3101_CR24","doi-asserted-by":"publisher","first-page":"eabb5883","DOI":"10.1126\/scitranslmed.abb5883","volume":"12","author":"TR Sheahan","year":"2020","unstructured":"Sheahan, T. R. et al. An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. Sci. Transl. Med. 12, eabb5883 (2020).","journal-title":"Sci. Transl. Med."},{"key":"3101_CR25","doi-asserted-by":"publisher","first-page":"e02479","DOI":"10.1128\/AAC.02479-20","volume":"65","author":"SS Good","year":"2021","unstructured":"Good, S. S. et al. AT-527, a double prodrug of a guanosine nucleotide analog, is a potent inhibitor of SARS-CoV-2 in vitro and a promising oral antiviral for treatment of COVID-19. Antimicrob. Agents Chemother. 65, e02479\u201320 (2021).","journal-title":"Antimicrob. Agents Chemother."},{"key":"3101_CR26","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1093\/cid\/ciaa410","volume":"71","author":"H Chu","year":"2020","unstructured":"Chu, H. et al. Comparative replication and immune activation profiles of SARS-CoV-2 and SARS-CoV in human lungs: an ex vivo study with implications for the pathogenesis of COVID-19. Clin. Infect. Dis. 71, 1400\u20131409 (2020).","journal-title":"Clin. Infect. Dis."},{"key":"3101_CR27","doi-asserted-by":"publisher","first-page":"e14","DOI":"10.1016\/S2666-5247(20)30004-5","volume":"1","author":"H Chu","year":"2020","unstructured":"Chu, H. et al. Comparative tropism, replication kinetics, and cell damage profiling of SARS-CoV-2 and SARS-CoV with implications for clinical manifestations, transmissibility, and laboratory studies of COVID-19: an observational study. Lancet Microbe 1, e14\u2013e23 (2020).","journal-title":"Lancet Microbe"},{"key":"3101_CR28","doi-asserted-by":"publisher","first-page":"103125","DOI":"10.1016\/j.ebiom.2020.103125","volume":"62","author":"Y Wang","year":"2020","unstructured":"Wang, Y. et al. Phase 2a, open-label, dose-escalating, multi-center pharmacokinetic study of favipiravir (T-705) in combination with oseltamivir in patients with severe influenza. EBioMedicine 62, 103125 (2020).","journal-title":"EBioMedicine"},{"key":"3101_CR29","doi-asserted-by":"publisher","first-page":"W488","DOI":"10.1093\/nar\/gkaa216","volume":"48","author":"A Ianevski","year":"2020","unstructured":"Ianevski, A., Giri, A. K. & Aittokallio, T. SynergyFinder 2.0: visual analytics of multi-drug combination synergies. Nucl. Acids Res. 48, W488\u2013W493 (2020).","journal-title":"Nucl. Acids Res."},{"key":"3101_CR30","unstructured":"Ju, J. et al. Therapeutics for COVID-19. PCT patent application WO 2021155119 (A2). (2021)."},{"key":"3101_CR31","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.ijbiomac.2020.12.038","volume":"168","author":"N Narayanan","year":"2021","unstructured":"Narayanan, N. & Nair, D. T. Ritonavir may inhibit exoribonuclease activity of nsp14 from the SARS-CoV-2 virus and potentiate the activity of chain terminating drugs. Int. J. Biol. Macromol. 168, 272\u2013278 (2021).","journal-title":"Int. J. Biol. Macromol."},{"key":"3101_CR32","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1056\/NEJMoa2001282","volume":"382","author":"B Cao","year":"2020","unstructured":"Cao, B. et al. A trial of Lopinavir\u2013Ritonavir in adults hospitalized with severe Covid-19. N. Engl. J. Med. 382, 1787\u20131799 (2020).","journal-title":"N. Engl. J. Med."},{"key":"3101_CR33","unstructured":"Essam, A. Comparison of remdesivir versus lopinavir\/ritonavir and remdesivir combination in COVID-19 patients. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04738045 (2021)."},{"key":"3101_CR34","doi-asserted-by":"crossref","first-page":"e10196","DOI":"10.1002\/btm2.10196","volume":"6","author":"A Blasiak","year":"2020","unstructured":"Blasiak, A. et al. IDentif.AI: rapidly optimizing combination therapy design against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with digital drug development. Bioeng. Transl. Med. 6, e10196 (2020).","journal-title":"Bioeng. Transl. Med."},{"key":"3101_CR35","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1111\/cts.12840","volume":"13","author":"RSafety Humeniuk","year":"2020","unstructured":"Humeniuk, R. Safety tolerability, and pharmacokinetics of Remdesivir, an antiviral for treatment of COVID-19, in healthy subjects. Clin. Transl. Sci. 13, 896\u2013906 (2020).","journal-title":"Clin. Transl. Sci."},{"key":"3101_CR36","doi-asserted-by":"publisher","first-page":"e1009226","DOI":"10.1371\/journal.ppat.1009226","volume":"17","author":"J Gribble","year":"2021","unstructured":"Gribble, J. et al. The coronavirus proofreading exoribonuclease mediates extensive viral recombination. PLoS Pathog. 17, e1009226 (2021).","journal-title":"PLoS Pathog."},{"key":"3101_CR37","doi-asserted-by":"publisher","unstructured":"Baddock, H. T. et al. Characterization of the SARS-CoV-2 ExoN (nsp14ExoN-nsp10) complex: implications for its role in viral genome stability and inhibitor identification. Nucl. Acids Res. https:\/\/doi.org\/10.1093\/nar\/gkab1303 (2022).","DOI":"10.1093\/nar\/gkab1303"},{"key":"3101_CR38","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1021\/acsptsci.1c00022","volume":"4","author":"T Chen","year":"2021","unstructured":"Chen, T. et al. Synergistic inhibition of SARS-CoV-2 replication using disulfiram\/ebselen and remdesivir. ACS Pharmacol. Transl. Sci. 4, 898\u2013907 (2021).","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"3101_CR39","doi-asserted-by":"publisher","first-page":"109133","DOI":"10.1016\/j.celrep.2021.109133","volume":"35","author":"K Bafna","year":"2021","unstructured":"Bafna, K. et al. Hepatitis C virus drugs that inhibit the SARS-CoV-2 papain-like protease synergize with Remdesivir to suppress viral replication in cell culture. Cell Rep. 35, 109133 (2021).","journal-title":"Cell Rep."},{"key":"3101_CR40","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1038\/s41467-021-21992-w","volume":"12","author":"JS Driouich","year":"2021","unstructured":"Driouich, J. S. et al. Favipiravir antiviral efficacy against SARS-CoV-2 in a hamster model. Nat. Comm. 12, 1735 (2021).","journal-title":"Nat. Comm."},{"key":"3101_CR41","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.mjafi.2020.08.004","volume":"76","author":"U Agrawal","year":"2020","unstructured":"Agrawal, U., Raju, R. & Udwadia, Z. F. Favipiravir: a new and emerging antiviral option in COVID-19. Med. J. Armed Forces India 76, 370\u2013376 (2020).","journal-title":"J. Armed Forces India"},{"key":"3101_CR42","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.antiviral.2013.09.015","volume":"100","author":"Y Furuta","year":"2013","unstructured":"Furuta, Y. et al. Favipiravir (T-705), a novel viral polymerase inhibitor. Antivir. Res. 100, 446\u2013454 (2013).","journal-title":"Antivir. Res."},{"key":"3101_CR43","doi-asserted-by":"publisher","first-page":"449","DOI":"10.2183\/pjab.93.027","volume":"93","author":"Y Furuta","year":"2017","unstructured":"Furuta, Y. et al. Favipiravir (T-705), a broad-spectrum inhibitor of viral RNA polymerase. Proc. Jpn. Acad. Ser. B Phys. Biol. Sci. 93, 449\u2013463 (2017).","journal-title":"Proc. Jpn. Acad. Ser. B Phys. Biol. Sci."},{"key":"3101_CR44","doi-asserted-by":"publisher","first-page":"e2021946118","DOI":"10.1073\/pnas.2021946118","volume":"118","author":"K Naydenova","year":"2021","unstructured":"Naydenova, K. et al. Structure of the SARS-CoV-2 RNA-dependent RNA polymerase in the presence of favipiravir-RTP. Proc. Natl. Acad. Sci. USA. 118, e2021946118 (2021).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"3101_CR45","first-page":"100080","volume":"2","author":"Q Peng","year":"2021","unstructured":"Peng, Q. et al. Structural basis of SARS-CoV-2 polymerase inhibition by favipiravir. Innov. N. Y. 2, 100080 (2021).","journal-title":"Innov. N. Y."},{"key":"3101_CR46","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1056\/NEJMoa2116044","volume":"386","author":"A Jayk Bernal","year":"2022","unstructured":"Jayk Bernal, A. et al. Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients. N. Engl. J. Med. 386, 509\u2013520 (2022).","journal-title":"N. Engl. J. Med"},{"key":"3101_CR47","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1038\/s41467-022-28113-1","volume":"13","author":"A Shannon","year":"2022","unstructured":"Shannon, A. et al. A dual mechanism of action of AT-527 against SARS-CoV-2 polymerase. Nat. Commun. 13, 621 (2022).","journal-title":"Nat. Commun."},{"key":"3101_CR48","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/j.cell.2020.04.026","volume":"181","author":"D Blanco-Melo","year":"2020","unstructured":"Blanco-Melo, D. et al. Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell 181, 1036\u20131045 (2020).","journal-title":"Cell"},{"key":"3101_CR49","doi-asserted-by":"publisher","first-page":"9436","DOI":"10.1073\/pnas.1508686112","volume":"112","author":"Y Ma","year":"2015","unstructured":"Ma, Y. et al. Structural basis and functional analysis of the SARS coronavirus nsp14\u2013nsp10 complex. Proc. Natl. Acad. Sci. USA. 112, 9436\u20139441 (2015).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"3101_CR50","doi-asserted-by":"publisher","first-page":"D571","DOI":"10.1093\/nar\/gku1207","volume":"43","author":"J Brister","year":"2015","unstructured":"Brister, J., Ako-Adjei, D., Bao, Y. & Blinkova, O. NCBI viral genomes resource. Nucl. Acids Res. 43, D571\u2013D577 (2015).","journal-title":"Nucl. Acids Res"}],"container-title":["Communications Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s42003-022-03101-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-022-03101-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-022-03101-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T17:34:19Z","timestamp":1700242459000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s42003-022-03101-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,22]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["3101"],"URL":"https:\/\/doi.org\/10.1038\/s42003-022-03101-9","relation":{},"ISSN":["2399-3642"],"issn-type":[{"value":"2399-3642","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,22]]},"assertion":[{"value":"4 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"154"}}